Drugs / TSB-9-W1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02249650 | Jul 2017 → Feb 2020 | colorectal cancer | Taiwan Sunpan Biotechnology Development Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TSB-9-W1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02249650 ↗ |
| Known as | IDS | “The trade name of TSB-9-W1 is "IDS" in English, the registration number is 01472800 at 2011 by Intellectual Property Office (IPO), Taiwan.” NCT02249650 ↗ |
| Route | Oral | “Each treatment cycle is composed by a contiguous 2-day oral administration and a contiguous 3-day rest.” NCT02249650 ↗ |